Abstracts tagged "Lung Fibrosis"

Abstract Number: 1858 • ACR Convergence 2021
Serum Interferon Score Is a Biomarker of Active Disease in Patients with Early Diffuse Cutaneous Systemic Sclerosis Enrolled in the Prospective Registry of Early Systemic Sclerosis (PRESS) Cohort
Monique Hinchcliff¹, Suiyuan Huang², Shervin Assassi³, Elana Bernstein⁴, Flavia Castelino⁵, Robyn Domsic⁶, Tracy Frech⁷, Jessica Gordon⁸, Faye Hant⁹, Ami Shah¹⁰, Victoria Shanmugam¹¹, Virginia Steen¹², Dinesh Khanna² and Francesco Del Galdo¹³, ¹Yale School of Medicine, Westport, CT, ²University of Michigan, Ann Arbor, MI, ³University of Texas McGovern Medical School at Houston, Houston, TX, ⁴Columbia University, New York, NY, ⁵Massachusetts General Hospital, Boston, MA, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷University of Utah, Salt Lake City, UT, ⁸Hospital for Special Surgery, New York, NY, ⁹Medical University of South Carolina, Charleston, SC, ¹⁰Johns Hopkins Rheumatology, Baltimore, MD, ¹¹The George Washington University, Great Falls, VA, ¹²Division of Rheumatology, Georgetown University, Washington, DC, ¹³University of Leeds, Leeds, United Kingdom
Background/Purpose: Several published studies have demonstrated activation of the interferon type 1 (IFN) pathway in sera from patients with systemic sclerosis (SSc). Specifically, levels of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].